Translate

Tuesday, October 2, 2018

thumbnail

TOPS TOP Ships Inc. gains 15% Oct 2, 2018

Top Ships Inc. provides seaborne transportation services worldwide. It owns and operates medium range tanker vessels that transport crude oil, petroleum products, and bulk liquid chemicals. The company transports petroleum products and crude oil for the oil industry. As of December 31, 2016, it had a fleet of two chartered-in 49,737 deadweight ton (dwt) product/chemical tankers vessels, the M/T Stenaweco Energy and the M/T Stenaweco Evolution; two 39,208 dwt product/chemical tankers vessels, the M/T Eco Fleet and the M/T Eco Revolution; and two 49,737 dwt product/chemical tankers, the M/T Stenaweco Excellence and M/T Nord Valiant. The company was formerly known as Top Tankers Inc. and changed its name to Top Ships Inc. in December 2007. Top Ships Inc. was founded in 2000 and is based in Maroussi, Greece.http://www.priceseries.com/trade/TOPS-TOP-Ships-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2018091820181002.html
thumbnail

RLGT Radiant Logistics, Inc. gains 22% Oct 2, 2018

Radiant Logistics, Inc., a third party logistics company, provides multi-modal transportation and logistics services primarily in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services; and freight brokerage services, including truckload services, less than truckload services, and intermodal services. It also provides other value-added logistics services, such as customs brokerage, order fulfillment, inventory management, and warehouse and distribution services. The company offers its services to the consumer goods, food and beverage, manufacturing, and retail customers through a network of company-owned and strategic operating partner locations operating under the Radiant, Wheels, Airgroup, Adcom, DBA, and Service By Air brands. Radiant Logistics, Inc. was founded in 2001 and is headquartered in Bellevue, Washington.http://www.priceseries.com/trade/RLGT-Radiant-Logistics-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2018091220181002.html
thumbnail

OLLI Ollies Bargain Outlet Holdings, Inc. gains 26% Oct 2, 2018

Ollie's Bargain Outlet Holdings, Inc. operates as a retailer of brand name merchandise. The company offers food products, housewares, books and stationery products, bed and bath products, floor coverings, electronics, and toys; and other products, including hardware, personal health care, candy, clothing, sporting goods, pet products, luggage, automotive, seasonal, furniture, summer furniture, and lawn and garden. As of January 28, 2017, it operated 234 Ollie's Bargain Outlet locations across 19 states in the United States. The company was formerly known as Bargain Holdings, Inc. and changed its name to Ollie's Bargain Outlet Holdings, Inc. in March 2015. Ollie's Bargain Outlet Holdings, Inc. was founded in 1982 and is headquartered in Harrisburg, Pennsylvania.http://www.priceseries.com/trade/OLLI-Ollies-Bargain-Outlet-Holdings-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2018081720181002.html
thumbnail

MESO Mesoblast Limited gains 21% Oct 2, 2018

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. The company's lead product candidates include MPC-150-IM, a Phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; MPC-06-ID, a Phase 3 product candidate under investigation for the treatment of chronic low back pain due to disc degeneration; MSC-100-IV, a Phase 3 intravenously-delivered product candidate, which is developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation; and MPC-300-IV, an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy, which is under Phase 2 trial. It has a collaboration agreement with JCR Pharmaceuticals Co., Ltd to offer TEMCELL HS. Inj., a product based on its proprietary mesenchymal lineage adult stem cell technology for the treatment of graft versus host disease. The company has operations in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was founded in 2004 and is based in Melbourne, Australia.http://www.priceseries.com/trade/MESO-Mesoblast-Limited-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018091720181002.html
thumbnail

MBOT Microbot Medical Inc. gains 21% Oct 2, 2018

Microbot Medical Inc., a medical device company, engages in the research, design, development, and commercialization of micro-robotics medical technologies. Its ViRob and TipCAT platforms consist of micro-robotic technologies, from which the company is developing its product candidates, including the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH); and a self-propelling, semi-disposable endoscope that is being developed initially for use in colonoscopy procedures. The company was founded in 2010 and is based in Yokneam, Israel.http://www.priceseries.com/trade/MBOT-Microbot-Medical-Inc-stock-gains-21-percent-a-Trade-Record-by-priceSeries-2018091820181002.html
thumbnail

GHDX Genomic Health, Inc. gains 25% Oct 2, 2018

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has a collaboration agreement with Epic Sciences, Inc. The company was founded in 2000 and is based in Redwood City, California.http://www.priceseries.com/trade/GHDX-Genomic-Health-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2018081720181002.html
thumbnail

CHMA Chiasma, Inc. gains 26% Oct 2, 2018

Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.http://www.priceseries.com/trade/CHMA-Chiasma-Inc-stock-gains-26-percent-a-Trade-Record-by-priceSeries-2018091320181002.html

TradeVisor Product Review

Review I II III IV

Blog Archive